The RPL18 antibody targets ribosomal protein L18 (RPL18), a component of the 60S large subunit of eukaryotic ribosomes. RPL18 plays a critical role in ribosome assembly, stability, and translation by facilitating rRNA binding and peptide bond formation during protein synthesis. As part of the conserved ribosomal protein family, RPL18 is essential for cellular proliferation and homeostasis. Antibodies against RPL18 are widely used in research to study ribosome biogenesis, translational regulation, and their dysregulation in diseases. For example, altered RPL18 expression has been linked to cancers, developmental disorders, and neurodegenerative conditions, making it a biomarker of interest. These antibodies are validated for techniques like Western blotting, immunofluorescence, and immunoprecipitation to detect RPL18's localization (primarily nucleoli and cytoplasm) and expression levels. Studies also utilize RPL18 antibodies to explore ribosomopathies, where defective ribosome assembly triggers cellular stress pathways. Available as monoclonal or polyclonal variants from multiple host species, RPL18 antibodies are critical tools for dissecting the molecular interplay between ribosome dysfunction and disease mechanisms.